Cargando…
Prolactinomas: evolution after menopause
OBJETIVE: The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolacti...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118912/ https://www.ncbi.nlm.nih.gov/pubmed/26909481 http://dx.doi.org/10.1590/2359-3997000000138 |
_version_ | 1785028904946237440 |
---|---|
author | Mallea-Gil, Maria Susana Manavela, Marcos Alfieri, Analia Ballarino, Maria Carolina Chervin, Alberto Danilowicz, Karina Diez, Sabrina Day, Patricia Fainstein García-Basavilbaso, Natalia Glerean, Mariela Guitelman, Mirtha Katz, Débora Loto, Monica Graciela Martinez, Marcela Miragaya, Karina Moncet, Daniel Rogozinski, Amelia Susana Servidio, Marisa Stalldecker, Graciela Vitale, Marcelo Boero, Laura |
author_facet | Mallea-Gil, Maria Susana Manavela, Marcos Alfieri, Analia Ballarino, Maria Carolina Chervin, Alberto Danilowicz, Karina Diez, Sabrina Day, Patricia Fainstein García-Basavilbaso, Natalia Glerean, Mariela Guitelman, Mirtha Katz, Débora Loto, Monica Graciela Martinez, Marcela Miragaya, Karina Moncet, Daniel Rogozinski, Amelia Susana Servidio, Marisa Stalldecker, Graciela Vitale, Marcelo Boero, Laura |
author_sort | Mallea-Gil, Maria Susana |
collection | PubMed |
description | OBJETIVE: The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period. Age at menopause was 49 ± 3.6 years. The average time of treatment was 135 ± 79 months. The time of follow-up after treatment suspension was 4 to 192 months. RESULTS: Pre-treatment PRL levels in micro and macroadenomas were 119 ± 57 ng/mL and 258 ± 225 ng/mL, respectively. During menopause after treatment suspension, and at the latest follow-up: in microadenomas PRL levels were 23 ± 13 ng/mL and 16 ± 5.7 ng/mL, respectively; in macroadenomas, PRL levels were 20 ± 6.6 ng/mL (5t5)and 25 ± 18 ng/mL, respectively. In menopause after treatment suspension, the microadenomas had disappeared in 9/22 and had decreased in 13/22. In the group of patients whose tumor had decreased, in the latest follow-up, tumors disappeared in 7/13 and remained unchanged in 6/13. In macroadenomas, after treatment suspension 3/7 had disappeared, 3/7 decreased and 1/7 remained unchanged. In the latest control in the 3 patients whose tumor decreased, disappeared in 1/3, decreased in 1/3 and there was no change in the remaining. CONCLUSIONS: Normal PRL levels and sustained reduction or disappearance of adenomas were achieved in most of patients, probably due to the decrease of estrogen levels. Dopamine agonists might be stopped after menopause in patients with prolactinomas. |
format | Online Article Text |
id | pubmed-10118912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Sociedade Brasileira de Endocrinologia e Metabologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-101189122023-04-21 Prolactinomas: evolution after menopause Mallea-Gil, Maria Susana Manavela, Marcos Alfieri, Analia Ballarino, Maria Carolina Chervin, Alberto Danilowicz, Karina Diez, Sabrina Day, Patricia Fainstein García-Basavilbaso, Natalia Glerean, Mariela Guitelman, Mirtha Katz, Débora Loto, Monica Graciela Martinez, Marcela Miragaya, Karina Moncet, Daniel Rogozinski, Amelia Susana Servidio, Marisa Stalldecker, Graciela Vitale, Marcelo Boero, Laura Arch Endocrinol Metab Original Article OBJETIVE: The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period. Age at menopause was 49 ± 3.6 years. The average time of treatment was 135 ± 79 months. The time of follow-up after treatment suspension was 4 to 192 months. RESULTS: Pre-treatment PRL levels in micro and macroadenomas were 119 ± 57 ng/mL and 258 ± 225 ng/mL, respectively. During menopause after treatment suspension, and at the latest follow-up: in microadenomas PRL levels were 23 ± 13 ng/mL and 16 ± 5.7 ng/mL, respectively; in macroadenomas, PRL levels were 20 ± 6.6 ng/mL (5t5)and 25 ± 18 ng/mL, respectively. In menopause after treatment suspension, the microadenomas had disappeared in 9/22 and had decreased in 13/22. In the group of patients whose tumor had decreased, in the latest follow-up, tumors disappeared in 7/13 and remained unchanged in 6/13. In macroadenomas, after treatment suspension 3/7 had disappeared, 3/7 decreased and 1/7 remained unchanged. In the latest control in the 3 patients whose tumor decreased, disappeared in 1/3, decreased in 1/3 and there was no change in the remaining. CONCLUSIONS: Normal PRL levels and sustained reduction or disappearance of adenomas were achieved in most of patients, probably due to the decrease of estrogen levels. Dopamine agonists might be stopped after menopause in patients with prolactinomas. Sociedade Brasileira de Endocrinologia e Metabologia 2016-01-01 /pmc/articles/PMC10118912/ /pubmed/26909481 http://dx.doi.org/10.1590/2359-3997000000138 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Mallea-Gil, Maria Susana Manavela, Marcos Alfieri, Analia Ballarino, Maria Carolina Chervin, Alberto Danilowicz, Karina Diez, Sabrina Day, Patricia Fainstein García-Basavilbaso, Natalia Glerean, Mariela Guitelman, Mirtha Katz, Débora Loto, Monica Graciela Martinez, Marcela Miragaya, Karina Moncet, Daniel Rogozinski, Amelia Susana Servidio, Marisa Stalldecker, Graciela Vitale, Marcelo Boero, Laura Prolactinomas: evolution after menopause |
title | Prolactinomas: evolution after menopause |
title_full | Prolactinomas: evolution after menopause |
title_fullStr | Prolactinomas: evolution after menopause |
title_full_unstemmed | Prolactinomas: evolution after menopause |
title_short | Prolactinomas: evolution after menopause |
title_sort | prolactinomas: evolution after menopause |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118912/ https://www.ncbi.nlm.nih.gov/pubmed/26909481 http://dx.doi.org/10.1590/2359-3997000000138 |
work_keys_str_mv | AT malleagilmariasusana prolactinomasevolutionaftermenopause AT manavelamarcos prolactinomasevolutionaftermenopause AT alfierianalia prolactinomasevolutionaftermenopause AT ballarinomariacarolina prolactinomasevolutionaftermenopause AT chervinalberto prolactinomasevolutionaftermenopause AT danilowiczkarina prolactinomasevolutionaftermenopause AT diezsabrina prolactinomasevolutionaftermenopause AT daypatriciafainstein prolactinomasevolutionaftermenopause AT garciabasavilbasonatalia prolactinomasevolutionaftermenopause AT glereanmariela prolactinomasevolutionaftermenopause AT guitelmanmirtha prolactinomasevolutionaftermenopause AT katzdebora prolactinomasevolutionaftermenopause AT lotomonicagraciela prolactinomasevolutionaftermenopause AT martinezmarcela prolactinomasevolutionaftermenopause AT miragayakarina prolactinomasevolutionaftermenopause AT moncetdaniel prolactinomasevolutionaftermenopause AT rogozinskiameliasusana prolactinomasevolutionaftermenopause AT servidiomarisa prolactinomasevolutionaftermenopause AT stalldeckergraciela prolactinomasevolutionaftermenopause AT vitalemarcelo prolactinomasevolutionaftermenopause AT boerolaura prolactinomasevolutionaftermenopause |